Compare Gilead Sciences, Inc. (GILD) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs T-Mobile Us Inc — how do they compare? Gilead Sciences, Inc. trades at $133.06 (market cap $163.51B), while T-Mobile Us Inc trades at $192.57 (market cap $203.04B). The key difference: T-Mobile Us Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TMUS | |
|---|---|---|
Market Cap | $163.51B | $203.04B |
Sector | Health | Media |
52-Week High | $155.80 | $259.01 |
52-Week Low | $108.22 | $167.65 |
Enterprise Value | $178.05B | $320.74B |
Dividend Yield | 2.49% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
T-Mobile US (TMUS) trades at $187.13, down 0.68% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The company reported strong Q1 2026 earnings of $2.27 per share, beating expectations, and maintains robust fundamentals with 2025 revenue of $88.31 billion and net income of $10.99 billion. Recent leadership changes and positive analyst coverage highlight ongoing strategic growth initiatives.
The outlook for TMUS remains positive with an 83% analyst buy rating and a consensus price target of $241.27, suggesting significant upside. Key risks include rising debt levels, competitive pressures from satellite internet providers like Starlink, and potential margin compression. The stock presents a growth opportunity supported by strong cash flow and market positioning, though investors should monitor execution against these challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
